Pay in 4 interest-free payments of $7.48 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Retatrutide is a novel 39-amino acid peptide developed as a triple receptor agonist (GLP-1, GIP and glucagon receptors)
While technically covered, it won't be approved for your indication
"The 44% reduction in all-cause mortality observed among patients with obesity and co-occurring autoimmune disease is a striking finding that demands our attention, said Fatima Cody Stanford, M.D., M.P.H., M.P.A., M.B.A., FAHA and member of the American Heart Associations Lifestyle and Cardiometabolic Council
People with active cancer or a history of certain cancers Pregnant or nursing women Children and adolescents under 18 People with certain pituitary, thyroid, or adrenal conditions Anyone with severe diabetes or uncontrolled blood sugar People taking medications that may interact with growth hormone peptides Our Medical Director reviews your full health history during your consultation to make sure peptide therapy is safe for you
Labelled glucagon-like peptide-1 analogues: past, present and future
